CStone Pharmaceuticals-B Surges Over 20% by Late Morning on Strong CS2009 Lung Cancer Efficacy Data

Deep News11:50

CStone Pharmaceuticals-B (02616) saw its gains expand to over 20% by late morning. At the time of writing, the stock was up 20.29%, trading at HK$8.30, with a turnover of HK$390 million.

The company announced the latest clinical progress of its self-developed PD-1/VEGF/CTLA-4 trispecific antibody, CS2009. Preliminary efficacy data from the Phase I/II trial of CS2009 as a monotherapy for lung cancer were positive. In first-line non-small cell lung cancer (NSCLC) patients with a PD-L1 tumor proportion score (TPS) ≥50%, the objective response rate (ORR) reached 90%, and the disease control rate (DCR) was 100%. Among immunotherapy (IO) pretreated, driver gene (AGA) negative second-line and later-line NSCLC patients, the ORR was 25%.

Based on these results, CStone Pharmaceuticals plans to initiate the first Phase III global multi-center clinical trial (MRCT) for CS2009 by the end of 2026, focusing on indications such as NSCLC, colorectal cancer (CRC), and small cell lung cancer (SCLC). Further Phase I and Phase II clinical research data for CS2009 are expected to be presented in 2026 at the American Society of Clinical Oncology (ASCO) Annual Meeting and/or the European Society for Medical Oncology (ESMO) Congress.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135867297?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 11:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135867297","market":"other","top_or_hot":-1,"title":"CStone Pharmaceuticals-B Surges Over 20% by Late Morning on Strong CS2009 Lung Cancer Efficacy Data","media":"Deep News","content":"<p>CStone Pharmaceuticals-B (02616) saw its gains expand to over 20% by late morning. At the time of writing, the stock was up 20.29%, trading at HK$8.30, with a turnover of HK$390 million.</p>\n<p>The company announced the latest clinical progress of its self-developed PD-1/VEGF/CTLA-4 trispecific antibody, CS2009. Preliminary efficacy data from the Phase I/II trial of CS2009 as a monotherapy for lung cancer were positive. In first-line non-small cell lung cancer (NSCLC) patients with a PD-L1 tumor proportion score (TPS) ≥50%, the objective response rate (ORR) reached 90%, and the disease control rate (DCR) was 100%. Among immunotherapy (IO) pretreated, driver gene (AGA) negative second-line and later-line NSCLC patients, the ORR was 25%.</p>\n<p>Based on these results, CStone Pharmaceuticals plans to initiate the first Phase III global multi-center clinical trial (MRCT) for CS2009 by the end of 2026, focusing on indications such as NSCLC, colorectal cancer (CRC), and small cell lung cancer (SCLC). Further Phase I and Phase II clinical research data for CS2009 are expected to be presented in 2026 at the American Society of Clinical Oncology (ASCO) Annual Meeting and/or the European Society for Medical Oncology (ESMO) Congress.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CStone Pharmaceuticals-B Surges Over 20% by Late Morning on Strong CS2009 Lung Cancer Efficacy Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCStone Pharmaceuticals-B Surges Over 20% by Late Morning on Strong CS2009 Lung Cancer Efficacy Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-03-27 11:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CStone Pharmaceuticals-B (02616) saw its gains expand to over 20% by late morning. At the time of writing, the stock was up 20.29%, trading at HK$8.30, with a turnover of HK$390 million.</p>\n<p>The company announced the latest clinical progress of its self-developed PD-1/VEGF/CTLA-4 trispecific antibody, CS2009. Preliminary efficacy data from the Phase I/II trial of CS2009 as a monotherapy for lung cancer were positive. In first-line non-small cell lung cancer (NSCLC) patients with a PD-L1 tumor proportion score (TPS) ≥50%, the objective response rate (ORR) reached 90%, and the disease control rate (DCR) was 100%. Among immunotherapy (IO) pretreated, driver gene (AGA) negative second-line and later-line NSCLC patients, the ORR was 25%.</p>\n<p>Based on these results, CStone Pharmaceuticals plans to initiate the first Phase III global multi-center clinical trial (MRCT) for CS2009 by the end of 2026, focusing on indications such as NSCLC, colorectal cancer (CRC), and small cell lung cancer (SCLC). Further Phase I and Phase II clinical research data for CS2009 are expected to be presented in 2026 at the American Society of Clinical Oncology (ASCO) Annual Meeting and/or the European Society for Medical Oncology (ESMO) Congress.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1135867297","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135867297","pubTimestamp":1774583426,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"CStone Pharmaceuticals-B (02616) saw its gains expand to over 20% by late morning. At the time of writing, the stock was up 20.29%, trading at HK$8.30, with a turnover of HK$390 million. The company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02616":"基石药业-B","BK1574":"生物医药B类股"},"translate_title":"CS2009肺癌疗效数据强劲，基石药业-B上午晚些时候飙升超过20%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02616":1},"content_text":"CStone Pharmaceuticals-B (02616) saw its gains expand to over 20% by late morning. At the time of writing, the stock was up 20.29%, trading at HK$8.30, with a turnover of HK$390 million.\nThe company announced the latest clinical progress of its self-developed PD-1/VEGF/CTLA-4 trispecific antibody, CS2009. Preliminary efficacy data from the Phase I/II trial of CS2009 as a monotherapy for lung cancer were positive. In first-line non-small cell lung cancer (NSCLC) patients with a PD-L1 tumor proportion score (TPS) ≥50%, the objective response rate (ORR) reached 90%, and the disease control rate (DCR) was 100%. Among immunotherapy (IO) pretreated, driver gene (AGA) negative second-line and later-line NSCLC patients, the ORR was 25%.\nBased on these results, CStone Pharmaceuticals plans to initiate the first Phase III global multi-center clinical trial (MRCT) for CS2009 by the end of 2026, focusing on indications such as NSCLC, colorectal cancer (CRC), and small cell lung cancer (SCLC). Further Phase I and Phase II clinical research data for CS2009 are expected to be presented in 2026 at the American Society of Clinical Oncology (ASCO) Annual Meeting and/or the European Society for Medical Oncology (ESMO) Congress.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135867297","isCrawlerRequest":true}